Small Cell Lung Cancer News and Research

RSS
Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

From Cell Signaling Technology 24 Feb 2011
Cannabis Science extract treatments help kill cancer cells

Cannabis Science extract treatments help kill cancer cells

23 Feb 2011
OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

14 Feb 2011
Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

8 Feb 2011
FDA approves Hospira's topotecan for SCLC

FDA approves Hospira's topotecan for SCLC

3 Feb 2011
AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO receives USAN, WHO generic name approval for ficlatuzumab

3 Feb 2011
Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

3 Feb 2011
Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

1 Feb 2011
Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

28 Jan 2011
Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

28 Jan 2011
Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

28 Jan 2011
ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

24 Jan 2011
Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

21 Jan 2011
ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

20 Jan 2011
FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

20 Jan 2011
Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

19 Jan 2011
New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

19 Jan 2011
Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

13 Jan 2011
Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

12 Jan 2011
Epigenetic therapy holds promise for cancer management

Epigenetic therapy holds promise for cancer management

12 Jan 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback